anti vegf  (Proteintech)

Journal: Lab on a Chip

Article Title: Label-free assessment of a microfluidic vessel-on-chip model with visible-light optical tomography reveals structural changes in vascular networks

doi: 10.1039/d5lc00927h

Figure Lengend Snippet: Time-resolved imaging of vascular network development in vessel-on-chip by optical coherence tomography. A) Timeline of disease modeling. Vessel-on-chips were loaded and vessels were allowed to grow for 2 days. Thereafter, the vascular network was subjected to control medium, medium with high glucose and added TNF-α and IL-6, and VEGF medium for 3 more days. Vessel-on-chips were measured every day after day 2. B) Minimum intensity projections, showing the change in the vascular network in the control condition over the course of 5 days. C) Minimum intensity projections, displaying changes in vascular network for the high glucose condition on day 4 and 5. D) Minimum intensity projections, exhibiting changes in the vascular network for the VEGF condition on day 4 and 5. For a full overview of the process, see Fig. S2 in SI. Representative images shown, scale bar = 500 μm.

Article Snippet: On day 3, vascular specification was induced by adding 50 ng ml −1 vascular endothelial growth factor (VEGF) (Miltenyi Biotec, Germany) and 10 μM SB431542 (Tocris Bioscience, UK) in BPEL medium to the cells.

Techniques: Imaging, Tomography, Control

Journal: Lab on a Chip

Article Title: Label-free assessment of a microfluidic vessel-on-chip model with visible-light optical tomography reveals structural changes in vascular networks

doi: 10.1039/d5lc00927h

Figure Lengend Snippet: Change in vessel thickness in the vessel-on-chip over the treatment period, for the different treatments. A) Control condition on day 2 to 5, B) high glucose with added TNF-α and IL-6 condition on day 4 to 5, and C) VEGF treatment on day 4 to 5. For a full overview of the process, see Fig. S3 in SI. Representative images shown, scale bar = 500 μm.

Article Snippet: On day 3, vascular specification was induced by adding 50 ng ml −1 vascular endothelial growth factor (VEGF) (Miltenyi Biotec, Germany) and 10 μM SB431542 (Tocris Bioscience, UK) in BPEL medium to the cells.

Techniques: Control

Journal: Lab on a Chip

Article Title: Label-free assessment of a microfluidic vessel-on-chip model with visible-light optical tomography reveals structural changes in vascular networks

doi: 10.1039/d5lc00927h

Figure Lengend Snippet: Overlay of the variation in the number of branches and vessel length under the different conditions during treatment of the vessel-on-chip for A) the control condition on day 2 to 5, B) the high glucose with added TNF-α and IL-6 condition on day 4 and 5, and C) the VEGF condition on day 4 to 5. For a full overview of the process, see Fig. S4 in SI. Representative images shown, scale bar = 500 μm.

Article Snippet: On day 3, vascular specification was induced by adding 50 ng ml −1 vascular endothelial growth factor (VEGF) (Miltenyi Biotec, Germany) and 10 μM SB431542 (Tocris Bioscience, UK) in BPEL medium to the cells.

Techniques: Control

Journal: Lab on a Chip

Article Title: Label-free assessment of a microfluidic vessel-on-chip model with visible-light optical tomography reveals structural changes in vascular networks

doi: 10.1039/d5lc00927h

Figure Lengend Snippet: Quantitative properties of the vascular network during treatment for all conditions. A) Vascularity index (VI), B) mean thickness, C) total vessel length, and D) number of branching points. Data are presented in boxplots from four individual microfluidic chips ( n = 4). Statistical analyses were performed using one-way ANOVA followed by a Student's t -test. * indicates p < 0.05. E) Minimum intensity projections from Fig. S2 showing the change in the vascular network in the control, high glucose with added TNF-α and IL-6, and VEGF condition over the course of 5 days. Representative images shown, scale bar = 500 μm.

Article Snippet: On day 3, vascular specification was induced by adding 50 ng ml −1 vascular endothelial growth factor (VEGF) (Miltenyi Biotec, Germany) and 10 μM SB431542 (Tocris Bioscience, UK) in BPEL medium to the cells.

Techniques: Control

Journal: iScience

Article Title: 3D-printed scaffold loaded with baicalin exosomes promotes bone defect repair via mediating PRRX2 to alleviate inflammation

doi: 10.1016/j.isci.2025.113565

Figure Lengend Snippet: Identification and angiogenesis of exos from BA-pretreated BMSCs (A) The morphology of BMSC-exos and BA-BMSC-exos under transmission electron microscopy. (B) Nanoparticle tracking analysis showing the size distribution of BMSC-exos and BA-BMSC-exos. (C) The expression levels of the exosome markers CD9, TSG101, and CD81 were measured by western blot. (D) The uptake of BA-BMSC-exos by HUVECs was detected by immunofluorescence staining (scale bar: 100 μm). (E) CCK8 determined the viability of HUVECs after treatment with exos. (F) Cell migration of HUVECs determined by Transwell assay (scale bar: 100 μm). (G) Tube formation of HUVECs following treatment with exos (scale bar: 100 μm). The expression of VEGF and CD31 in HUVECs was determined by (H) Western blot and (I) qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way or two-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: After washing three times, the membranes were stained with primary antibodies against CD9, TSG101, CD31, p -AKT, AKT, IL-6, IL-1β, TNF-α, Nrf2, and HO-1 (all from Abcam, UK), vascular endothelial growth factor (VEGF) (from Proteintech, USA) overnight at 4 °C.

Techniques: Transmission Assay, Electron Microscopy, Expressing, Western Blot, Immunofluorescence, Staining, Migration, Transwell Assay, Standard Deviation

Journal: iScience

Article Title: 3D-printed scaffold loaded with baicalin exosomes promotes bone defect repair via mediating PRRX2 to alleviate inflammation

doi: 10.1016/j.isci.2025.113565

Figure Lengend Snippet: Effects of 3D-β-TCP scaffolds loaded with exos on angiogenesis and osteogenesis in vivo (A–C) HE staining and Masson staining analysis of the formation of new bone after implantation with a scaffold for 8 weeks (B and C) The expression levels of IL-6, TNF-α, VEGF, and CD31 were determined by immunohistochemistry staining and qPCR. Data are presented as mean ± standard deviation (SD), n = 3, p -values are calculated using one-way ANOVA, ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001.

Article Snippet: After washing three times, the membranes were stained with primary antibodies against CD9, TSG101, CD31, p -AKT, AKT, IL-6, IL-1β, TNF-α, Nrf2, and HO-1 (all from Abcam, UK), vascular endothelial growth factor (VEGF) (from Proteintech, USA) overnight at 4 °C.

Techniques: In Vivo, Staining, Expressing, Immunohistochemistry, Standard Deviation

Journal: Cellular and Molecular Gastroenterology and Hepatology

Article Title: Targeting LOXL1-expressing Hepatic Stellate Cell Inhibits Fibrogenesis and Sinusoid Angiogenesis via LOXL1/RUNX1/VEGFA Axis During Progression of Liver Fibrosis

doi: 10.1016/j.jcmgh.2025.101637

Figure Lengend Snippet: The VEGFA-integrin axis mediates LOXL1-driven HSC-endothelial crosstalk. ( A ) Experimental design. Transwell coculture system of LX2 and EA.hy926 cells with bevacizumab (anti-human VEGFA monoclonal antibody) treatment of LX2 cells. ( B–E ) Bevacizumab prevents LOXL1-induced upregulation of COL4A1, COL4A2, COL5A1, and LAMC1 in EA.hy926 cells cocultured with LOXL1-expressing LX2 cells. ( F ) Experimental design: Transwell coculture of LX2 and EA.hy926 cells with RGD peptide treatment of EA.hy926 cells. ( G–J ) RGD peptide prevents LOXL1-induced upregulation of COL4A1, COL4A2, COL5A1 and LAMC1 in EA.hy926 cells cocultured with LOXL1-expressing LX2 cells. Data are presented as mean ± SEM. Statistical analysis was conducted using 1-way ANOVA; ∗ P < .05, ∗∗ P < .01, ∗∗∗ P < .001.

Article Snippet: To investigate the VEGFA-integrin axis in LX2-EA.hy926 communication, EA.hy926 cells were pretreated with RGD peptide (MCE, HY-P1740, 10 μM) for 12 hours or LX2 cells pretreated with anti-Human VEGF (Bevacizumab) (MCE, HY-P9906A, 25 μg/mL) for 12 hours, followed by 2 PBS washes.

Techniques: Expressing